Renovaro Introduces Augusta, an AI-Powered Platform for Precision Neurology
Thursday, May 15, 2025
Renovaro Inc, a company focused on AI-driven precision medicine for cancer and neurological conditions, has introduced Augusta, a new platform designed to improve diagnosis, treatment, and research in neurology. The platform helps with patient grouping, biomarker discovery, drug development, and validation.
Augusta supports a field that has long faced difficulties due to unclear symptoms, limited biomarkers, and complex disease patterns. It is built on Renovaro’s existing Cube and Elion platforms and has already been used in work related to Parkinson’s disease and epilepsy.
The platform uses a combination of technologies and methods:
- Data Preprocessing: Augusta is the first machine learning platform focused on biomedicine that can quickly and efficiently prepare data. Its patented method helps reduce bias and improve results in drug development, diagnostics, and precision treatments.
- Phenoclustering: It groups patient-level clinical and symptom data into clear subgroups that are biologically and clinically meaningful.
- Biomarker Identification: It brings together different types of data and applies predictive analytics to find biomarkers, including clinical traits and molecular features. Proprietary AI models are used to detect gene mutations and epigenetic changes.
- In Silico Screening: This method uses generative models to simulate how thousands of genes might react to disruption, reducing the need for lab experiments and animal testing.
- Closed-Loop Validation: Using CRISPR-modified zebrafish, the platform tests gene and small molecule effects on brain development and behaviour. It also checks for possible side effects in specific genetic backgrounds, supported by advanced computer vision tools.
Augusta has been developed to be transparent, clinically focused, and well tested. Its modular design allows different AI models, including large language models, to be integrated and tested easily using Renovaro’s knowledge graphs. This makes it possible to keep updating the platform while ensuring reliable performance.
Early use of Augusta in Parkinson’s disease helped identify new patient subgroups with distinct symptoms and biomarkers. In epilepsy, the platform found new drug candidates for patients with rare genetic mutations.
Renovaro now aims to extend Augusta’s capabilities to other neurological conditions. The company is currently in discussions with academic medical centres and life sciences organisations to form new partnerships.
Source: globenewswire.com
